Ribociclib plus endocrine therapy boosts survival of HR+/HER2- breast cancer
The MONALEESA-7 trial showed for the first time that adding a CDK4/6 inhibitor, ribociclib, to endocrine therapy significantly extends overall survival in metastatic hormone receptor-positive, HER2-negative breast cancer. The trial was unique in enrolling only premenopausal women under 59, a group in which about two-thirds of metastatic breast cancers are hormone receptor-positive. Median overall survival was not reached with ribociclib versus about 40 months with placebo; a landmark analysis at 42 months, an easier figure to explain to patients, found 70.2% of the ribociclib group alive versus 46% on placebo. No biomarker yet identifies patients who will not benefit from CDK4/6 inhibition. Activation of the PI3K pathway is suspected in primary or acquired resistance, so trials are adding PI3K pathway inhibitors, though more drugs mean more toxicity, and the aim is to find the subset who truly need them. This belongs to medical oncology, specifically targeted therapy for hormone receptor-positive metastatic breast cancer.